Zimmer Biomet Holdings (NYSE:ZBH) reported robust first-quarter 2026 financial results on Tuesday, April 28, 2026, outperforming market expectations driven by a recovery in elective surgery volumes and the continued adoption of its ROSA robotic technology.
The medical device leader posted net sales of $2.087 billion, representing a 9.3% increase on a reported basis and a 2.9% increase on an organic constant currency basis compared to the prior-year period.
The company reported GAAP net earnings of $238.1 million, while adjusted net earnings reached $409.4 million.
Diluted earnings per share (EPS) stood at $1.22, with adjusted diluted EPS coming in at $2.09.
The strong performance across its core Knee and Hip segments was bolstered by the successful rollout of the Persona OsseoTi and the expansion of the ZBEdge digital ecosystem.
Zimmer Biomet’s cash generation remained a highlight of the quarter, with $359.4 million in operating cash flow and $245.9 million in free cash flow.
Maintaining its commitment to capital allocation, the company repurchased $250 million of its common stock during the quarter, signaling management's confidence in the firm's long-term valuation.
Buoyed by the start of the year, Zimmer Biomet raised its full-year 2026 financial guidance.
The company now expects adjusted diluted EPS to range between $8.15 and $8.35, an upward revision from previous estimates.
Additionally, free cash flow expectations were raised to a range of $1.1 billion to $1.2 billion.